OncoMatch/Clinical Trials/NCT06575296
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
Is NCT06575296 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Revumenib for acute leukemia.
Treatment: Revumenib — This phase I trial tests the safety, side effects, best dose and effectiveness of revumenib in treating patients with acute leukemia after allogeneic stem cell transplant. Revumenib is in a class of medications called menin inhibitors. Revumenib targets and binds to the protein menin, thereby preventing the interaction between menin and the mixed lineage leukemia protein. Disrupting this interaction prevents the activation of specific genes that fuel the development of leukemia cells and inhibits the survival, growth, and production of certain kinds of leukemia cells. Giving revumenib may be safe, tolerable, and/or effective in treating patients with acute leukemia after allogeneic stem cell transplant.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: NPM1 mutation
Confirmed NPM1m AML with at least one of the following additional characteristics
Required: KMT2A (MLL) rearrangement
Confirmed KMT2Ar acute leukemia obtained by fluorescence in situ hybridization (11q23 MLL-break apart fluorescence in situ hybridization [FISH]) or next-generation sequencing (NGS)
Allowed: FLT3 ITD co-mutation
FLT3-ITD co-mutation
Performance status
ECOG/KARNOFSKY/LANSKY 0–2
ECOG =< 2 or Karnofsky Performance Status (KPS) >= 70, or a Lansky Performance Score of >= 70 (if aged < 18 years)
Prior therapy
Must have received: allogeneic stem cell transplant — scheduled or completed
PATIENTS WHO ARE SCHEDULED TO UNDERGO HEMATOPOIETIC CELL TRANSPLANTATION (HCT) OR THOSE WHO HAVE UNDERGONE HCT
Cannot have received:
Prior diagnosis of acute promyelocytic leukemia
Lab requirements
Blood counts
Hemoglobin >= 9 (no transfusion/growth factors to achieve); Platelets >= 75,000 (no transfusion/growth factors to achieve); ANC >= 500 for 3 days (fully engrafted, no GCSF to meet criteria)
Kidney function
Creatinine clearance >= 60 mL/min per 24 hour urine test or Cockcroft-Gault formula
Liver function
Total bilirubin <= 1.5 x ULN (<= 3.0 x ULN if < 75 years); AST <= 2.5 x ULN; ALT <= 2.5 x ULN
Cardiac function
QTcF <= 450 msec (males) or <= 470 msec (females); Ejection fraction (EF) >= 50% by echocardiogram or MUGA
Hemoglobin (Hgb) >= 9. Platelets >= 75 thousand (k). ANC >= 500 for 3 days. Total bilirubin <= 1.5 x ULN (<= 3.0 x ULN if < 75 years). AST <= 2.5 x ULN. ALT <= 2.5 x ULN. QTcF <= 450 msec (males) or <= 470 msec (females). Ejection fraction (EF) >= 50%. Creatinine clearance >= 60 mL/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- City of Hope Medical Center · Duarte, California
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify